SIRT1 and inflammatory bowel disease: No significant changes were observed in the expression levels of K2P5.1 transcripts (n = 4, p = 0.6124) (Figure 7A) in the splenic CD4+ T cells of IBD model mice, treated with 1 μM of vorinostat, a pan-HDAC inhibitor, and 50 μM of NCO-01, an SIRT1/2 inhibitor for 24 h.